Effect of Livergol on Taxane Induced Nephropathy in Breast cancer ?

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N133

Enrollment

100

Registered

2020-03-02

Start date

2018-10-12

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of nipple and areola, unspecified female breast

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive from the beginning of the second phase of chemotherapy for one month after the end of chemotherapy with 3 coated ta

Eligibility

Sex/Gender

Female

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Breast cancer 20 to 60 years Histopathologic view of breast cancer No catching to diabetes Lack of anemia Absence of apparent deformity of the lower extremities No Chronic Metabolic Disorders Not taking anti-neuropathic medicines such as Gabapentin or Pregabalin

Exclusion criteria

Exclusion criteria: Dissatisfaction

Design outcomes

Primary

Measure	Time frame
Nephropathy. Timepoint: Before starting the plan and receiving chemotherapy, one month, three months and six months after chemotherapy. Method of measurement: Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatolah Mohaghegh

Arak University of Medical Sciences

Mohagheghfrt@yahoo.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026